Literature DB >> 30975480

Activity Level Does Not Affect Survivorship of Unicondylar Knee Arthroplasty at 5-Year Minimum Follow-Up.

David A Crawford1, Joanne B Adams1, Adolph V Lombardi2, Keith R Berend3.   

Abstract

BACKGROUND: Patients are often cautioned against a high level of activity after knee arthroplasty. The purpose of this study was to report on implant survivorship and outcomes of high-activity patients compared with low-activity patients after unicondylar knee arthroplasty (UKA).
METHODS: We identified 487 patients (576 knees) who underwent UKA with the Oxford mobile bearing knee (Zimmer Biomet, Warsaw, IN) with a 5-year minimum follow-up. Patients were divided into 2 groups: low activity (LA) (University of California Los Angeles ≤6) and high activity (HA) (University of California Los Angeles ≥7). Preoperative and postoperative range of motion, Knee Society scores, complications, and reoperations were evaluated.
RESULTS: Mean follow-up was 9 years (range, 4 to 13.1). The HA group had significantly more male patients, were younger, and had higher knee society clinical scores and knee society functional scores preoperatively. The HA group had significantly higher improvements in Knee Society scores and pain postoperatively. Revisions were performed in 8.4% of the LA group and 6.2% of the HA group (P = .43). At our mean of 9-year follow-up, there was 94.0% survival for the HA group and 92.1% for the LA group (P = .6085).
CONCLUSIONS: Highly active patients had no increased risk of revision after UKA with the Oxford mobile bearing knee at 5-year minimum follow-up.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  activity; arthroplasty; knee; survivorship; unicondylar

Mesh:

Year:  2019        PMID: 30975480     DOI: 10.1016/j.arth.2019.03.038

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  6 in total

1.  Large variability in recommendations for return to daily life activities after knee arthroplasty among Dutch hospitals and clinics: a cross-sectional study.

Authors:  A Carlien Straat; Denise J M Smit; Pieter Coenen; Gino M M J Kerkhoffs; Johannes R Anema; P Paul F M Kuijer
Journal:  Acta Orthop       Date:  2022-06-20       Impact factor: 3.925

2.  Does Activity Level After Primary Total Hip Arthroplasty Affect Aseptic Survival?

Authors:  David A Crawford; Joanne B Adams; Gerald R Hobbs; Michael J Morris; Keith R Berend; Adolph V Lombardi
Journal:  Arthroplast Today       Date:  2021-08-23

3.  Robotic arm-assisted versus conventional medial unicompartmental knee arthroplasty: five-year clinical outcomes of a randomized controlled trial.

Authors:  Matthew Banger; James Doonan; Philip Rowe; Bryn Jones; Angus MacLean; Mark J B Blyth
Journal:  Bone Joint J       Date:  2021-06       Impact factor: 5.082

4.  Return to sports after medial unicompartmental knee arthroplasty in patients with concomitant patella-femoral osteoarthritis: multicenter retrospective cohort study with minimum 5-year follow-up.

Authors:  Massoni Carlo; Casciano Eduardo; Basile Attilio; Zanini Antonio; Bettinsoli Pierfrancesco; Marconi Alessandro; Maiotti Marco; Russo Raffaele; Amato Massimiliano; Santoro Giuseppe; Marco Spoliti; Riccardo Maria Lanzetti
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-03-15

5.  Therapeutic Effects Comparison and Revision Case Analysis of Unicompartmental Knee Arthroplasty and Open Wedge High Tibial Osteotomy in Treating Medial Knee Osteoarthritis in Patients Under 60 years: A 2-6-year Follow-up Study.

Authors:  Zhang Ziqi; Mei Yufeng; Zhang Lei; Wang Chunsheng; Yang Pei; Wang Kunzheng
Journal:  Orthop Surg       Date:  2020-09-06       Impact factor: 2.071

Review 6.  Comparable incidence of periprosthetic tibial fractures in cementless and cemented unicompartmental knee arthroplasty: a systematic review and meta-analysis.

Authors:  Joost A Burger; Tjeerd Jager; Matthew S Dooley; Hendrik A Zuiderbaan; Gino M M J Kerkhoffs; Andrew D Pearle
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-02-02       Impact factor: 4.342

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.